Heparin and heparan sulfate have been shown to block nerveinduced acetylcholine-receptor (AChR) aggregation at developing neuromuscular junctions. We found that heparin, heparan sulfate, and a wide variety of other polyanions also inhibited agrin-induced AChR aggregation. The more highly charged the polyanion, the more potent it was as an inhibitor. Inhibition of agrin-induced AChR aggregation was due, at least in part, to the formation of a complex between the polyanion and agrin that was inactive. These findings are consistent with the hypothesis that nerve-induced aggregation of AChRs is mediated by the release of agrin, or a closely related protein, from axon terminals and suggest that a polyanion, such as a sulfated proteoglycan, may be involved in the interaction of agrin with its receptor on the myotube surface.
During the formation of the vertebrate skeletal neuromuscular junction, the axon terminal signals the developing myofiber to assemble a postsynaptic apparatus at the site of nerve-muscle contact (Dennis, 198 1) . This postsynaptic specialization is characterized by high concentrations ofcytoplasmic, membrane, and extracellular-matrix components, including aggregates of acetylcholine receptors (AChRs) in the myofiber's plasma membrane and accumulations of AChE in the synaptic basal lamina (Fertuck and Salpeter, 1974; McMahan et al., 1978) . Little is known about the mechanism of formation of the postsynaptic apparatus or the signals that induce it. The most thoroughly studied aspect of postsynaptic differentiation is nerve-induced accumulation of AChRs, which requires Ca2+ (Henderson et al., 1984) and occurs, at least in part, by lateral migration of AChRs in the myotube plasma membrane (Anderson and Cohen, 1977; Ziskind-Conhaim et al., 1984; Kuromi et al., 1985 ; but see Role et al., 1985) . In addition, Hirano and Kidokoro (1989) have reported that heparin and heparan sulfate block nerve-induced AChR aggregation in Xenopus nerve-muscle cocultures. They speculated that heparin and heparan sulfate did not interfere directly with the mechanism by which muscle cells formed ag-gregates of AChRs, but rather disrupted the signaling between the axon terminal and the muscle cell.
One candidate for such a signal is agrin, a protein purified from the electric organ of Torpedo cafifornica (Godfrey et al., 1984; Nitkin et al., 1987) . Agrin, or a closely related protein, is found in the cell bodies of spinal motor neurons, both in the embryo and in the adult McMahan, 1988, 1989) , is transported down motor axons (Magill-Sole and McMahan, 1989) , and, when added to myotubes in culture, induces the formation of specializations on their surface at which several components of the postsynaptic apparatus are aggregated, including AChRs and AChE (Godfrey et al., 1984; Wallace et al., 1985; Wallace, 1986 Wallace, , 1989 . Agrin-induced aggregation of AChRs requires Ca*+ and occurs by lateral migration (Godfrey et al., 1984; Wallace, 1988) . These and other findings have led to the hypothesis that agrin is released from axon terminals at developing neuromuscular junctions to induce the differentiation of the postsynaptic apparatus and becomes incorporated into the synaptic basal lamina, where it serves to maintain those specializations in the adult and direct their formation during regeneration (Nitkin et al., 1987; Reist et al., 1987; Wallace, 1988; McMahan and Wallace, 1989) .
To gain insight into how heparin and heparan sulfate might prevent accumulation of AChRs, we studied the effects of these and other polyanions on agrin-induced AChR aggregation. We found that heparin and heparan sulfate inhibited agrin-induced AChR aggregation. We also found that a wide variety of polyanions mimicked the effects of heparin and heparan sulfate, and that polyanion inhibition of agrin-induced AChR aggregation was due, at least in part, to the formation of a complex between the polyanion and agrin that was inactive.
Materials and Methods
Chick myotube cultures. Myotube cultures were prepared from hindlimb muscles-of 1 I-12-d-old White Leghorn chick embryos by the method of Fischbach (1972) . with minor modifications (Wallace. 1989). Exneriments were routinely made on U-d-old myoiube cultures that were transferred to defined medium [a 1: 1 mixture of Dulbecco's Modified Eagle's Medium and Ham's nutrient mixture F-12 (DME/Fl2) (Sigma Chemical Co., St. Louis, MO) supplemented with 0.8 mM CaCl,, 1 mg/ ml BSA (RIA grade, Sigma), 100 U/ml penicillin, and 0.1 mg/ml streptomycin] on the day of the experiment.
Agrin. Most experiments were made with partially purified preparations of agrin (Cibacron pool) prepared from the electric organ of Torpedo californica as previously described (Nitkin et al., 1987) . For experiments on binding to derivatized Sephadex and Sepharose beads, agrin was purified on a monoclonal-antibody 6D4 immunoaffinity resin as previously described (Nitkin et al., 1987) , except that the final eluate was immediately neutralized with l/10 vol 1 M T&Cl (pH, 7.6) to preserve activity.
QuantiJication ofAChR aggregation. AChR aggregates were visualized and counted as previously described (Wallace, 1986 (Wallace, , 1988 
Results
Heparin inhibits agrin-induced AChR aggregation Hirano and Kidokoro (1989) have shown that addition of heparin or heparan sulfate to nerve-muscle cocultures inhibits the accumulation of AChRs at sites of nerve-muscle contact. To determine the effect of heparin on agrin-induced AChR aggregation, heparin was added to chick-myotube cultures together with agrin, the cultures were incubated for 15 hr, then the distribution of AChRs was visualized using rhodamine a-bungarotoxin. As illustrated in Figures 1 and 2 , 0.05 mg/ml heparin prevented agrin-induced AChR aggregation. Myotubes exposed to heparin were indistinguishable from controls by phase-contrast microscopy, and heparin had no discernible effect on the number or size of spontaneously occurring AChR aggregates. This suggests that inhibition of AChR aggregation by heparin was not the result of some general cytotoxic effect.
Eficts of heparin are reversible
To determine the extent to which the effects of heparin were reversible, myotubes were incubated with medium containing 0.05 mg/ml heparin for 15 hr, rinsed twice, then treated with agrin for 7 hr in normal medium. Pretreatment with heparin had no discernible effect on the subsequent response of myotubes to agrin (Fig. 2) , providing further evidence that inhibition of agrin-induced AChR aggregation by heparin is not due to cytotoxicity. Likewise, incubating agrin in 0.4 mg/ml heparin for 2 hr before adding it to myotube cultures had no effect on agrin's AChR-aggregating activity (Fig. 2) , indicating that heparin did not irreversibly inactivate or remove agrin from so- Heparin must be present together with agrin to inhibit AChR aggregation. Myotube cultures were treated for 15 hr with agrin (control) or agrin with 0.05 mg/ml heparin (heparin), and the number of AChR aggregates was determined. When added together with agrin, heparin completely blocked agrin-induced AChR aggregation. There was no change in the number of aggregates of AChRs induced by 7-hr treatment with agrin when either myotubes or agrin were pretreated with heparin (myotubes: incubated 15 hr in medium containing 0.05 mg/ml heparin, rinsed twice, then treated with agrin in normal medium; ugrin: 9 U Cibacron pool were incubated 2 hr in 45 rl medium containing 0.4 mpl ml heparin, then 15-~1 aliquots were added to myotube cultures containing 1.5 ml medium, giving a final heparin concentration of 0.004 mg/ml). Data, expressed as percent of control, are mean + SEM (N = 3). lution. Therefore, heparin must be present together with agrin in the myotube cultures to prevent AChR aggregation.
Heparin has no effect on the maintenance of agrin-induced AChR aggregates
Heparin might decrease the number of AChR aggregates in agrintreated cultures by preventing the formation ofAChR aggregates and/or by destabilizing aggregates so that they disperse as rapidly as they are formed. To examine directly the effects of heparin on aggregate stability, myotubes were pretreated with agrin overnight to induce aggregate formation, then agrin was removed, and the cultures were incubated for an additional 7 hr in normal medium or medium supplemented with 0.05 mg/ml heparin. When myotubes are cultured in normal medium, agrininduced AChR aggregates disappear slowly after agrin is removed (Wallace, 1988) . As illustrated in Figure 3 , heparin did not affect the disappearance of agrin-induced AChR aggregates. Therefore, heparin must reduce the number of AChR aggregates in agrin-treated cultures by inhibiting aggregate formation.
Inhibition of agrin-induced AChR aggregation by other polyanions
We next sought to determine the properties of heparin that were responsible for its inhibitory activity (Fig. 4) . We first examined the effects of other glycosaminoglycans. Heparan sulfate inhibited agrin-induced AChR aggregation, but was considerably less potent than heparin. Chondroitin sulfate also caused some inhibition of agrin-induced AChR aggregation, but only at much higher concentrations. Hyaluronic acid had no detectable effect at concentrations as high as 0.5 mg/ml. Therefore, the potency of glycosaminoglycans as inhibitors increased in parallel with their charge density (hyaluronic acid < chondroitin sulfate < heparan sulfate < heparin).
To test whether the repeating disaccharide structure of glycosaminoglycans was important for inhibition, a variety ofother carbohydrate polymers were tested. Dextran, an uncharged polymer ofglucose, was ineffective as an inhibitor, while dextran sulfate, which is more heavily sulfated than heparin, was a more potent inhibitor than heparin. Of the compounds investigated, the most potent inhibitor was fucoidin, a very heavily sulfated polymer of fucose. On the other hand, monomeric sulfated sugars (0.5 mg/ml) had little effect on agrin-induced AChR aggregation [D-glucosamine 2-sulfate, 94 f 9% of control (mean f SEM, N = 4); D-glucosamine 2,3-disulfate, 90 + 6%; D-glucosamine 2,6-disulfate, 9 1 f 5%], indicating that polymeric structure is important for inhibition.
Polyaspartic acid, a polymer of an amino acid rather than of sugar residues, was about as effective an inhibitor as chondroitin sulfate. Polyaspartic acid has about the same density of charged residues as chondroitin sulfate, but they are all carboxyl groups, indicating that neither a carbohydrate backbone nor sulfation is required for inhibition. Therefore, polyanions other than glycosaminoglycans inhibited agrin-induced AChR aggregation; the potency of a polyanion as an inhibitor appeared to be determined by the overall charge density of the molecule rather than the charged group itself (sulfate or carboxyl) or the nature of the polymeric backbone (fucose, glucose, glycosaminoglycan, or amino acid).
Mechanism of inhibition by polyanions
To characterize further how polyanions inhibited agrin's effects, we examined the dose dependence of agrin-induced AChR aggregation in the presence and absence of one of the most potent polyanionic inhibitors, dextran sulfate. As is illustrated in Figure  5 , the effect of dextran sulfate was to shift the dose-response curve to higher agrin concentrations. This pattern would result if polyanions such as dextran sulfate prevented agrin-induced AChR aggregation by inhibiting competitively the interaction of agrin with a receptor on the myotube surface or ifagrin formed a complex with the polyanion that was inactive.
To test the possibility that agrin formed inactive complexes with polyanions, we examined the binding of agrin to a variety of derivatized Sephadex and Sepharose beads (Fig. 6 ). Agrin and beads were mixed together in culture medium, then the beads were removed by centrifugation and the supematant assayed for AChR-aggregating activity. Beads bearing negatively charged residues removed approximately 60% of the agrin from the supematant, while uncharged beads or beads bearing positively charged residues bound little or no agrin. Therefore, agrin does bind to polyanions, and this could account, at least in part, for their inhibitory activity. As illustrated in Figure 7 , the binding of agrin to heparin-conjugated beads was reduced by approximately 30% in the absence of Ca2+, which might contribute to the Ca2+ dependence of agrin-induced AChR aggregation (see Discussion).
Discussion
Several lines of evidence suggest that, at developing neuromuscular junctions, agrin is released from axon terminals and combines with a receptor on the myotube surface to induce the formation of the postsynaptic apparatus (see McMahan and Wallace, 1989 (Hirano and Kidokoro, 1989) .
Mechanism of inhibition of agrin-induced AChR aggregation
Polyanions such as heparin have been shown to bind to a wide variety of glycoproteins, including members of the immunoglobulin gene superfamily (NCAM, CD2, CD4; Lederman et al., 1989) , anticoagulation factors (antithrombin III, heparan cofactor II, protein C inhibitor; Ofosu et al., 1989; Pratt et al., 1989) , extracellular matrix components (laminin: Skubitz et al., 1988; fibronectin: Rogers et al., 1985; vitronectin: Suzuki et al., 1985) and growth factors (aFGF, bFGF, Barzu et al., 1989; Burgess and Maciag, 1989) . Binding of polyanions to some proteins, such as laminin, appears to be selective for heparinlike glycosaminoglycan side chains, and this specificity may play a role in establishing the structure of the basal lamina and regulating the interaction of cells with it (Skubitz et al., 1988) . In many cases, however, binding of polyanions is much less selective, and polyanions that are clearly nonphysiological, such as sulfated dextran, bind with high affinity. For example, a variety of polyanions in addition to heparin inhibit competitively neural cell adhesion to an NCAM substrate (Cole and Glaser, 1986) and the interaction of CD4 with the gp 120 coat protein of HIV (Lederman et al., 1989) . These observations have led to the speculation that a variety of extracellular and cell-surface ligandreceptor interactions might be strengthened by the interaction of a polyanion binding site on the ligand with sulfated carbohydrate residues on the receptor (Lederman et al., 1989) . Our finding that polyanions bind to agrin and inhibit agrin-induced AChR aggregation is consistent with the hypothesis that a similar interaction is important for agrin's binding to and activation of its receptor.
The binding of agrin to such a polyanionic site on its receptor might be expected to depend on Ca2+ in a manner similar to Neutral (dextran) or lightly charged (hyaluronic acid) polymers had little or no effect on agrin-induced AChR aggregation; moderately (chondroitin sulfate) to intensely (hcoidin) charged polyanions were inhibitory. the binding of agrin to heparin beads, which could account, at least in part, for the requirement for Ca2+ in agrin-induced AChR aggregation (Wallace, 1988) .
The heparin-agarose beads used in the binding experiments contain 0.75 mg heparin per ml of packed gel. Eight ~1 of beads 100 agrin [units) Figure 5 . Polyanions shift the dose-response curve for agrin-induced AChR aggregation to higher concentrations. Myotube cultures were incubated overnight with the indicated concentration of agrin in normal medium or medium supplemented with 0.005 mg/ml dextran sulfate. AChRs were labeled with rhodamine cy-bungarotoxin, and the number of AChR aggregates was counted. Each data point is the mean of triplicate determinations; curves were fit by eye. . Agrin binds to negatively charged beads. Immunoaffinitypurified agrin (equivalent to 3 U/culture) was incubated with 8 ~1 beads in 40 ~1 culture medium for 1.5 hr, the beads were removed by centrifugation, and aliquots of the resulting supematant were added to myotube cultures overnight to assay for residual AChR-aggregating activity. Data, expressed as a percentage of the activity remaining after treatment with Sephadex G-50, are mean f SEM (N = 3). [In control experiments, 87 f 7% (mean -t SEM, N = 3) of the agrin remained in the supematant after incubation with Sephadex G-50 beads compared to no beads at all.] G50, Sephadex G-50 (50-l 50 pm), uncharged; DEAE, DEAE-Sephadex (A-50, 40-120 pm), positively charged; SP, SP-Sephadex (C-50, 40-l 20 pm), negatively charged (S04-2); HEP, heparinagarose (4% cross-linked beaded agarose), negatively charged; CM, CMSephadex (C-50, 100-200 mesh), negatively charged (COO-).
were incubated with 12 U agrin in a total vol of 40 ~1. If we assume that all the bound heparin is accessible, this corresponds to an average concentration of 0.15 mg/ml heparin. Under these conditions, the agrin concentration in the supematant was reduced by 80%, to 2.4 U. On the other hand, when added together with agrin to myotube cultures, 0.15 mg/ml heparin inhibited AChR aggregation 100%; only 0.02 mg/ml was required to reduce the effective agrin concentration by 80%. It is difficult to determine whether or not it is appropriate to make such a quantitative comparison between the binding of agrin to heparincoated beads and the inhibition of agrin-induced AChR aggregation by heparin in solution. Nevertheless, the apparent discrepancy raises the possibility that polyanions might inhibit agrin-induced AChR aggregation by some additional mecha; nism.
Dose-dependent inhibition of nerve-and agrin-induced AChR aggregation by polyanions Hirano and Kidokoro (1989) Figure 7 . Binding of agrin to heparin beads is reduced by removing Ca*+. Immunoaffinity-purified agrin (equivalent to 2 U/culture) was incubated with 8 ~1 beads in 40 ~1 culture medium -t 3 mM EGTA for 2 hr, the beads were removed by centrifugation, and aliquots of the supematant were added to myotube cultures and assayed for AChRaggregating activity. Data, expressed as a percentage of the activity remaining after incubation with control beads, are mean & SEM (N = 6). Control beads, 4% cross-linked agarose conjugated to normal mouse serum; heparin beads, 4% cross-linked agarose conjugated to heparin.
Heparin beads removed approximately
90% of the agrin in normal medium (from 2 to 0.2 U) and 60% of the agrln in Cal+-free medium (from 2 to 0.8 U).
sulfate were much more potent: 0.05 mg/ml heparin or heparan sulfate inhibited agrin-induced AChR aggregation by 100 and 35%, respectively. This difference might arise from the different species used in the 2 studies; Hirano and Kidokoro (1989) Anderson (1986) has shown that one of the first events in the formation ofthe neuromuscular junction is the nerve-induced removal ofa muscle-derived heparan sulfate proteoglycan that coats the myotube surface. Subsequently, heparin sulfate proteoglycans accumulate together with acetylcholine receptors at the developing neuromuscular junction and remain concentrated there in the adult (Anderson and Fambrough, 1983; Anderson et al., 1984; Anderson, 1986) . On the other hand, Gordon and Hall (1989a) have isolated a muscle-cell line that is deficient in sulfated proteoglycan synthesis and shown that agrin does not induce aggregates of AChRs on such cells, as it does on their normal counterparts (Gordon and Hall, 1989b) . However, neurons can induce neurite-associated AChR aggregates on the deficient cells (Lupa et al., 1989) . Our hypothesis that the binding of agrin to its receptor on the myotube surface is strengthened by the interaction of a polyanion binding site on agrin with a sulfated proteoglycan on its receptor provides a framework for interpreting these results. Removal of heparan sulfate proteoglycans by axons as they approach the myotube surface might prevent agrin being bound to inappropriate sites during the early stages of synaptogenesis. Accumulation of heparan sulfate proteoglycan after nerve-muscle contact is established could act as a buffer to aid in maintaining a high concentration of agrin in the synaptic basal lamina. The agrin receptor might lack its sulfated proteoglycan moeity in proteoglycan-deficient mutant myotubes, thus reducing the affinity of the receptor for agrin. This could account for the failure of agrin to induce AChR aggregation. Nerve-induced AChR aggregation might persist, however, owing to a higher concentration of agrin beneath axon terminals and/or to additional molecules (such as sulfated proteoglycans) supplied by the axon terminal. Indeed, vesicles in choline@ axon terminals contain a chondroitin sulfate proteoglycan that becomes exposed on the presynaptic terminal during transmitter release (Carlson et al., 1986; Carlson and Wight, 1987) , and PC-12 pheochromocytoma cells, sensory neurons, and CNS neurons have been shown to express on their surface and to secrete heparan sulfate proteoglycans (Matthew et al., 1985; Dow et al., 1988) . Accordingly, increasing the concentration of agrin or adding exogenous polyanions might restore the response to agrin in proteoglycan-deficient myotubes.
